Fibrogen Inc (KYNB) — 10-Q Filings
All 10-Q filings from Fibrogen Inc. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
FibroGen Swings to Profit on China Divestiture, R&D Plummets
— Nov 10, 2025 Risk: medium
FIBROGEN INC (KYNB) reported a significant turnaround, posting a net income of $200.6 million for the three months ended September 30, 2025, compared to a net l -
FibroGen Narrows Q2 Loss to $10.5M Amid Shifting Revenue Mix
— Aug 11, 2025 Risk: medium
FIBROGEN INC reported a net loss of $10.5 million for the three months ended June 30, 2025, a significant improvement from the net loss of $40.5 million for the -
FibroGen Inc. Files Q1 2025 10-Q
— May 12, 2025 Risk: medium
FibroGen Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and business operations, including information relat -
FibroGen Reports Q3 2024 Results
— Nov 12, 2024 Risk: medium
FibroGen Inc. reported its third-quarter results for the period ending September 30, 2024. The company's revenue from drug product sales in the United States an -
FibroGen Inc. Q2 2024 Update
— Aug 6, 2024 Risk: medium
FibroGen Inc. reported its second quarter 2024 results, ending June 30, 2024. The company's financial statements reflect various financial activities and invest -
FibroGen Inc. Files 10-Q for Period Ending March 31, 2024
— May 6, 2024 Risk: medium
FIBROGEN INC (KYNB) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. FibroGen Inc. filed a 10-Q report for the quarter ended March 31, 2024. The fil
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX